Adding an anti-inflammatory drug to anti-PD1 checkpoint inhibitor immunotherapy has shown great promise as a new strategy ...

Practice-changing studies in advanced non-small cell lung cancer presented at ASCO 2024 are reviewed by Dr Ticiana Leal, ...

Treatment for lung cancer has changed significantly with immunotherapy, an expert said during the CURE® Educated Patient® ...

For patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), standard use of the more accurate ...

Adding an anti-inflammatory drug to anti-PD1 checkpoint inhibitor immunotherapy has shown great promise as a new strategy against advanced lung cancer, based on results from a small clinical trial led ...

Results from a new study led by researchers at The University of Texas MD Anderson Cancer Center support standard use of the ...

“Such a combination is also approved for the management of advanced PD-L1-positive lung cancers. The same combination along with chemotherapy is also approved for all types of lung ...

And precision medicine will help us deliver better care.” MORE FROM THE SUMMIT: Understanding Immunotherapy and Side Effects ...

Our findings show it's time to routinely adopt IMRT over 3D-CRT for lung cancer, just like we did for prostate, anal and brain tumors decades ago. The improved precision of IMRT translates into real ...

Jen Dunlea, 22, is in a desperate fight for her life. She needs a lung transplant but has been rejected by most hospitals.

The following is a summary of “Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced ...

“The results from HERTHENA-Lung01 provide compelling evidence of efficacy of patritumab deruxtecan in heavily pretreated ...